» Articles » PMID: 32384773

Platelet Activation Is Triggered by Factors Secreted by Senescent Endothelial HMEC-1 Cells In Vitro

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 May 10
PMID 32384773
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Aging is one of the main risk factors for the development of chronic diseases, with both the vascular endothelium and platelets becoming functionally altered. Cellular senescence is a form of permanent cell cycle arrest initially described in primary cells propagated in vitro, although it can also be induced by anticancer drugs and other stressful stimuli. Attesting for the complexity of the senescent phenotype, senescent cells synthesize and secrete a wide variety of bioactive molecules. This "senescence-associated secretory phenotype" (SASP) endows senescent cells with the ability to modify the tissue microenvironment in ways that may be relevant to the development of various physiological and pathological processes. So far, however, the direct role of factors secreted by senescent endothelial cells on platelet function remains unknown. In the present work, we explore the effects of SASP factors derived from senescent endothelial cells on platelet function. To this end, we took advantage of a model in which immortalized endothelial cells (HMEC-1) were induced to senesce following exposure to doxorubicin, a chemotherapeutic drug widely used in the clinic. Our results indicate that (1) low concentrations of doxorubicin induce senescence in HMEC-1 cells; (2) senescent HMEC-1 cells upregulate the expression of selected components of the SASP and (3) the media conditioned by senescent endothelial cells are capable of inducing platelet activation and aggregation. These results suggest that factors secreted by senescent endothelial cells in vivo could have a relevant role in the platelet activation observed in the elderly or in patients undergoing therapeutic stress.

Citing Articles

The Multifaceted Role of Endothelial Sirt1 in Vascular Aging: An Update.

Campagna R, Mazzanti L, Pompei V, Alia S, Vignini A, Emanuelli M Cells. 2024; 13(17.

PMID: 39273039 PMC: 11394039. DOI: 10.3390/cells13171469.


The Role of Snake Venom Disintegrins in Angiogenesis.

Clissa P, Della-Casa M, Zychar B, Sanabani S Toxins (Basel). 2024; 16(3).

PMID: 38535794 PMC: 10974740. DOI: 10.3390/toxins16030127.


The Use of Triphenyl Phosphonium Cation Enhances the Mitochondrial Antiplatelet Effect of the Compound Magnolol.

Telleria F, Mansilla S, Mendez D, Sepulveda M, Araya-Maturana R, Castro L Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259359 PMC: 9958981. DOI: 10.3390/ph16020210.


Metformin mitigates SASP secretion and LPS-triggered hyper-inflammation in Doxorubicin-induced senescent endothelial cells.

Abdelgawad I, Agostinucci K, Sadaf B, Grant M, Zordoky B Front Aging. 2023; 4:1170434.

PMID: 37168843 PMC: 10164964. DOI: 10.3389/fragi.2023.1170434.


Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation.

Khavinson V, Linkova N, Dyatlova A, Kantemirova R, Kozlov K Cells. 2023; 12(1).

PMID: 36611900 PMC: 9818427. DOI: 10.3390/cells12010106.


References
1.
Parrinello S, Coppe J, Krtolica A, Campisi J . Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci. 2005; 118(Pt 3):485-96. PMC: 4939801. DOI: 10.1242/jcs.01635. View

2.
Di X, Shiu R, Newsham I, Gewirtz D . Apoptosis, autophagy, accelerated senescence and reactive oxygen in the response of human breast tumor cells to adriamycin. Biochem Pharmacol. 2009; 77(7):1139-50. DOI: 10.1016/j.bcp.2008.12.016. View

3.
Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S . Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. Cancer Cell. 2016; 30(4):533-547. PMC: 7789819. DOI: 10.1016/j.ccell.2016.09.003. View

4.
Minnema M, Breitkreutz I, Auwerda J, van der Holt B, Cremer F, van Marion A . Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia. 2004; 18(12):2044-6. DOI: 10.1038/sj.leu.2403533. View

5.
Sutherland D, Weitz I, Liebman H . Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003; 72(1):43-52. DOI: 10.1002/ajh.10263. View